Author:
Sandulache Vlad C.,Yang Liangpeng,Skinner Heath D.
Reference32 articles.
1. Dunn CJ, Peters DH (1995) Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49:721–749
2. Scheen AJ, Paquot N (2013) Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39:179–190
3. Salpeter S, Greyber E, Pasternak G, Salpeter E (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1, CD002967
4. Skinner HD, McCurdy MR, Echeverria AE et al (2013) Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52:1002–1009
5. Skinner HD, Sandulache VC, Ow TJ et al (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18:290–300